Abstract
There is an interplay between the cells in the bone marrow and the surrounding bone tissue, but little is known about the effects of myeloablative treatment followed by bone marrow transplantation on bone metabolism. We have therefore investigated 24 patients undergoing bone marrow transplantation (14 autologous, 10 allogeneic) for hematological malignancies. Serum concentrations of parathyroid hormone (PTH), albumin-modified calcium, and biomarkers for bone turnover-osteocalcin, bone alkaline phosphatase (B-ALP), and carboxyterminal cross-linked telopeptide of type I collagen (ICTP)-were measured. The samples were collected before myeloablative treatment, on the day of bone marrow infusion and 1, 2, 3, and 12 weeks thereafter. A serum PTH peak was consistently seen the day after total body irradiation, but no long-term effects on PTH/calcium homeostasis were observed. Bone formation as reflected by serum osteocalcin and B-ALP decreased, with nadir levels 2 to 3 weeks after marrow infusion. A simultaneous increase in bone resorption (increased S-ICTP) occurred. Pretreatment values were not completely regained 12 weeks after transplantation. the findings indicate that bone tissue is affected by myeloablative treatment, and the changes in biomarkers imply a net loss of bone over the study period.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Køther M, Schindler J, Oette K, Berthold F (1992) Abnormalities in serum osteocalcin values in children receiving chemotherapy including ifosfamide. In vivo 6:219–221
Reid IR, Chapman GE, Fraser TRC, Davies AD, Surus AS, Meyer J, Huq NL, Ibbertson HK (1986) Low serum osteocalcin levels in glucocorticoid-treated asthmatics. J Clin Endocrinol Metab 62:379–383
af Ekenstam E, Stålenheim G, Hällgren R (1988) The acute effect of high dose corticosteroid treatment on serum osteocalcin. Metabolism 37:141–144
Godschalk MF, Downs RW (1988) Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Miner Res 3:113–115
Duda RJ, O'Brien JF, Katzmann JA, Peterson JM, Mann KG, Riggs BL (1988) Concurrent assays of circulating bone glaprotein and bone alkaline phosphatase: effects of sex, age, and metabolic bone disease. J Clin Endocrinol Metab 66:951–957
Beresford JN, Gallagher JA, Gowen M, Couch M, Poser J, Wood DD, Russell RGG (1984) The effects of monocyte-conditioned medium and interleukin-1 on the synthesis of collagenous and non-collagenous proteins by mouse bone and human bone in vitro. Biochim Biophys Acta 7:58–65
Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factor. Nature 319: 516–518
Canalis E, McCarthy T, Centrella M (1988) Growth factors and the regulation of bone remodeling. J Clin Invest 81:277–281
Centrella M, McCarthy T, Canalis E (1988) Tumor necrosis factor-α inhibits collagen synthesis and alkaline phosphatase activity independently of its effects on deoxyribonucleic acid synthesis in osteoblast-enriched bone cultures. Endocrinology 123: 1442–1448
Stashenko P, Dewhirst FE, Rooney ML, Desjardins LA, Heeley JD (1987) Interleukin-1β is a potent inhibitor of bone formation in vitro. J Bone Miner Res 2:559–565
Zheng MH, Wood DJ, Papadimitriou JM (1992) What's new in the role of cytokines on osteoblast proliferation and differentiation? Pathol Res Pract 188:1104–1121
Yamasaki K, Solberg Jr L, Jamal N, Lockwood G, Trichler D, Curtis JE, Minden MM, Mann KG, Messner HA (1988) Hemopoietic colony growth-promoting activities in the plasma of bone marrow transplant recipients. Clin Invest 82:255–261
Rettie JE, Gottlieb D, Heslop HE, Leger O, Drexler HG, Hazlehurst G, Hoffbrand AV, Prentice HG, Brenner MK (1989) Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 73:1351–1358
Gowen M, Wood DD, Ihrie EJ, McGuire MKB, Russell RGG (1983) An interleukin 1-like factor stimulates bone resorption in vitro. Nature 306:378–380
Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L (1993) Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 39:635–640
Charles P, Mosekilde L, Risteli L, Risteli J, Eriksen EF (1994) Assessment of bone remodeling using biochemical indicators of type I collagen synthesis and degradation: relation to calcium kinetics. Bone Miner 24:81–94
Schlosberg M, Movsowitz C, Epstein S, Ismail F, Fallon MD, Thomas S (1988) The effects of cyclosporin A administration and its withdrawal on mineral metabolism in the rat. Endocrinology 124:2179–2183
Aubia J, Masramón J, Serrano S, Lloveras J, Marinoso LL (1988) Bone histology in renal transplant patients receiving cyclosporin. Lancet i:1048–1049
Burchard KW, Gann DS, Colliton J, Forster J (1990) Ionized calcium, parathormone and mortality in critically ill surgical patients. Ann Surg 212:543–550
Zaloga GP (1992) Hypocalcemia in critically ill patients. Crit Care Med 20:251–262
Kelley PJ, Atkinson K, Ward RL, Sambrook PN, Biggs JC, Eisman JA (1990) Reduced bone mineral density in men and women with allogeneic bone marrow transplantation. Transplantation 50:881–882
Reid IR (1989) Review. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol 30:83–103
Benker G, Schäfer U, Hermanns U, Mahmoud MK, Olbricht Th, Schulte HM, Windeck R, Reinwein D (1989) Allogeneic bone marrow transplantation in adults: endocrine sequelae after 1–6 years. Acta Endocrinol (Copenh) 120:37–42
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Carlson, K., Simonsson, B. & Ljunghall, S. Acute effects of high-dose chemotherapy followed by bone marrow transplantation on serum markers of bone metabolism. Calcif Tissue Int 55, 408–411 (1994). https://doi.org/10.1007/BF00298552
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00298552